Dataciencia

Colección SciELO Chile

Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation

Indexado

WoS	WOS:000866161300001
Scopus	SCOPUS_ID:85143644808

DOI

10.1093/EURJPC/ZWAC187

Año

2022

Tipo

artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras

Abstract

The position paper provides a summary of current understanding regarding the key risk factors, pathogenic mechanisms and clinical challenges relating to obesity and cardiovascular disease as seen from the viewpoint of the World Heart Federation and World Obesity Federation.

Revista

Revista	ISSN
European #Journal Of Preventive Cardiology	2047-4873

Métricas Externas

PlumX	Altmetric	Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Plumx: https://plumanalytics.com/learn/about-metrics/
Altmetric: https://www.altmetric.com/about-altmetrics/what-are-altmetrics/
Dimensions: https://www.dimensions.ai/why-dimensions/

Disciplinas de Investigación

WOS
Cardiac & Cardiovascular Systems
Cardiac & Cardiovascular System

Scopus
Sin Disciplinas

SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional

Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.

Autores - Afiliación

Ord.	Autor	Género	Institución - País
1	Lopez-Jimenez, Francisco	Hombre	Mayo Clin - Estados Unidos Mayo Clinic - Estados Unidos
2	Puri, Raman	Hombre	Cleveland Clin Abu Dhabi - Emiratos Árabes Unidos Universidad Finis Terrae - Chile Univ Lisbon - Portugal World Heart Federat - Suiza Cleveland Clinic Abu Dhabi - Emiratos Árabes Unidos Center for Advanced Metabolic Medicine and Nutrition - Chile Faculdade de Medicina, Universidade de Lisboa - Portugal World Heart Federation - Suiza School of Medicine Finis Terrae and San Sebastian Universities - Chile
3	Bays, Harold	Hombre	Louisville Metab & Atherosclerosis Res Ctr - Estados Unidos Louisville Metabolic and Atherosclerosis Research Center - Estados Unidos
4	Puri, Raman	Hombre	Cleveland Clin Abu Dhabi - Emiratos Árabes Unidos Universidad Finis Terrae - Chile Univ Lisbon - Portugal World Heart Federat - Suiza Cleveland Clinic Abu Dhabi - Emiratos Árabes Unidos Center for Advanced Metabolic Medicine and Nutrition - Chile Faculdade de Medicina, Universidade de Lisboa - Portugal World Heart Federation - Suiza School of Medicine Finis Terrae and San Sebastian Universities - Chile
5	Di Angelantonio, Emanuele	Hombre	UNIV CAMBRIDGE - Reino Unido Human Technopole - Italia Department of Public Health and Primary Care - Reino Unido Fondazione Human Technopole - Italia
6	le Roux, Carel W.	Hombre	Univ Coll Dublin - Irlanda University College Dublin - Irlanda
7	Sattar, Naveed	Hombre	Univ Glasgow - Reino Unido College of Medical, Veterinary & Life Sciences - Reino Unido
8	Sun, Marie Chan	Mujer	Univ Mauritius - Mauricio University of Mauritius - Mauricio
9	Wittert, G.	Hombre	Univ Adelaide - Australia Adelaide Medical School - Australia
10	Puri, Raman	Hombre	Cleveland Clin Abu Dhabi - Emiratos Árabes Unidos Universidad Finis Terrae - Chile Univ Lisbon - Portugal World Heart Federat - Suiza Cleveland Clinic Abu Dhabi - Emiratos Árabes Unidos Center for Advanced Metabolic Medicine and Nutrition - Chile Faculdade de Medicina, Universidade de Lisboa - Portugal World Heart Federation - Suiza School of Medicine Finis Terrae and San Sebastian Universities - Chile
11	Wilding, John P. H.	Hombre	Aintree Univ Hosp NHS Fdn Trust - Reino Unido Aintree University Hospital - Reino Unido

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento

Fuente
Novo Nordisk
ResMed Foundation

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos

Agradecimiento
The development of this paper was supported by an unrestricted educational grant from Novo Nordisk. Novo Nordisk was not involved in the preparation of this manuscript and had no control over the content.
Sanofi Aventis, Astra Zeneca, Janssen, Bristol-Myers Squibb, Boehringer-Ingelheim and Keyron. Professor Naveed Sattar has consulted for Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, and Sanofi; and received grant support paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics outside the submitted work. Dr Marie Chan Sun has no relevant financial disclosures. Professor Gary Wittert has received research support from Bayer, Lilly, Lawley Pharmaceuticals, Weight Watchers, ResMed Foundation, and Phillips. Speaker honoraria from Bayer, and Besins Healthcare. He is a member of an International and National Bayer advisory board. Professor Fausto Pinto has no relevant financial disclosures. Professor John PH Wilding undertakes consultancy and speaking engagements for industry contracted via the University of Liverpool (no personal payment) in relation to obesity and type 2 diabetes; in the last 2 years this includes work for Alnylam, AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Lilly, Napp, Novo Nordisk, Mundipharma, Pfizer, Rhythm Pharmaceuticals, Saniona and Ysopia (all modest). He is a named grant holder (at University of Liverpool) for research grants for clinical trials from AstraZeneca and Novo Nordisk (significant). He has received honoraria/lecture fees from AstraZeneca, Boehringer Ingelheim, Napp, Novo Nordisk, Mundipharma, Sanofi and Takeda (all modest).

Agradecimiento

The development of this paper was supported by an unrestricted educational grant from Novo Nordisk. Novo Nordisk was not involved in the preparation of this manuscript and had no control over the content.

Sanofi Aventis, Astra Zeneca, Janssen, Bristol-Myers Squibb, Boehringer-Ingelheim and Keyron. Professor Naveed Sattar has consulted for Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, and Sanofi; and received grant support paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics outside the submitted work. Dr Marie Chan Sun has no relevant financial disclosures. Professor Gary Wittert has received research support from Bayer, Lilly, Lawley Pharmaceuticals, Weight Watchers, ResMed Foundation, and Phillips. Speaker honoraria from Bayer, and Besins Healthcare. He is a member of an International and National Bayer advisory board. Professor Fausto Pinto has no relevant financial disclosures. Professor John PH Wilding undertakes consultancy and speaking engagements for industry contracted via the University of Liverpool (no personal payment) in relation to obesity and type 2 diabetes; in the last 2 years this includes work for Alnylam, AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Lilly, Napp, Novo Nordisk, Mundipharma, Pfizer, Rhythm Pharmaceuticals, Saniona and Ysopia (all modest). He is a named grant holder (at University of Liverpool) for research grants for clinical trials from AstraZeneca and Novo Nordisk (significant). He has received honoraria/lecture fees from AstraZeneca, Boehringer Ingelheim, Napp, Novo Nordisk, Mundipharma, Sanofi and Takeda (all modest).